Home / What’s new?

News & publications

Stay updated on the most recent developments in Symeres



Latest news

Amino acid synthesis at Symeres

Amino acid synthesis at Symeres

The biocatalysis toolbox at Symeres enables efficient access to a wide range of multifunctional, optically pure, unnatural amino acids and their derivatives.

Lipid chemistry at Symeres

Lipid chemistry at Symeres

Symeres has been supporting the global pharma and biotech industry with the synthesis and (ultra)-purification of these novel lipids. With the acquisition of Organix, we have significantly potentiated the platform.


Latest patents

Triazole derivatives and their use as tankyrase inhibitors

Number:
WO 2022/008896 A1

MEK Inhibitors and Therapeutic Uses Thereof

Number:
WO 2021/142144 A1

Novel Process

Number:
WO 2022/167817 A1

Latest publications

Rapid deracemization through solvent cycling: proof-of-concept using a racemizable conglomerate clopidogrel precursor

Article:
Chem Comm, xxx

The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window ] in Mouse Models

Article:
Cancer Research Communications (2022) 2 (4): 233–245.

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020 (Oncolines publication)

Article:
Front. Oncol., Sec. Cancer Molecular Targets and Therapeutics 12 – 2022

 
 

Development Centres of Excellence Network Lead Optimization Hit Generation Lead Optimization
 
 
 
 
 

Development Centres of Excellence Network Lead Optimization Hit Generation Lead Optimization
 
 
 
Scroll to top